Literature DB >> 2747922

Protective effect of cyclohexyl adenosine in treatment of cerebral ischemia in gerbils.

D K Januszewicz von Lubitz1, J M Dambrosia, D J Redmond.   

Abstract

The effect of postischemically injected cyclohexyl adenosine has been studied in gerbils. The animals were subjected to 30 min of bilateral carotid occlusion. Fifteen minutes after ischemia, one group of gerbils received a cerebroventricular injection of 251 of 0.5 M solution of cyclohexyl adenosine. The second group of ischemic animals was injected with the vehicle. After injections, the animals were randomly divided into two groups. Survival of one group of animals was monitored for 10 days. The second group was killed 5 days after ischemia, and the brains were used for a qualitative and quantitative histological evaluation. At the end of the 10-day monitoring period, 53% of the cyclohexyl adenosine-injected and 10% of the vehicle-injected ischemic animals were still alive (P less than 0.01, logrank test). Morphological preservation of the hippocampus and striatum was considerably improved in the cyclohexyl adenosine-treated animals (P less than 0.001, Student's t test). The nature of the protective effect of cyclohexyl adenosine is unknown, but it is suggested that reduction of neurotoxic excitatory amino acid release may be involved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747922     DOI: 10.1016/0306-4522(89)90265-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  15 in total

1.  Cerebral ischemia in gerbils: postischemic administration of cyclohexyl adenosine and 8-sulfophenyl-theophylline.

Authors:  D K von Lubitz; P J Marangos
Journal:  J Mol Neurosci       Date:  1990       Impact factor: 3.444

Review 2.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 3.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 4.  Release and actions of adenosine in the central nervous system.

Authors:  M J Higgins; H Hosseinzadeh; D G MacGregor; H Ogilvy; T W Stone
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Release of endogenous adenosine and its metabolites by the activation of NMDA receptors in the rat hippocampus in vivo.

Authors:  Y Chen; D I Graham; T W Stone
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

6.  Changes in extracellular adenosine levels and population spike amplitude during graded hypoxia in the rat hippocampal slice.

Authors:  J C Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

7.  Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor.

Authors:  D G MacGregor; W J Miller; T W Stone
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration.

Authors:  D G MacGregor; T W Stone
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

9.  Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.

Authors:  D K Von Lubitz; R C Lin; N Melman; X D Ji; M F Carter; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1994-04-21       Impact factor: 4.432

10.  Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.

Authors:  D K Von Lubitz; R C Lin; M Boyd; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.